Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SYNLOGIC, INC. Director's Dealing 2016

Mar 8, 2016

35028_dirs_2016-03-07_f4506e06-0c4d-4508-bd91-76ea87d1e920.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3/A — Form 3/A

Issuer: Mirna Therapeutics, Inc. (MIRN)
CIK: 0001527599
Period of Report: 2015-09-30

Reporting Person: Kim Sinil (Chief Medical Officer)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $4.35 2023-12-30 Common Stock (9062) Direct
Stock Option (Right to Buy) $8.10 2024-03-10 Common Stock (14566) Direct

Footnotes

F1: This Amendment is being filed solely to correct the balance of shares held by the reporting person with respect to the options restated herein. The aggregate total number of option shares held by the Reporting Person was correctly reported originally.

F2: The option vests with respect to 25% of the shares subject thereto on March 6, 2014, with the remaining shares vesting with respect to 1/48 of the total shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.

F3: The option vests with respect to 25% of the shares subject thereto on March 10, 2015, with the remaining shares vesting with respect to 1/48 of the total shares subject thereto on each monthly anniversary thereafter, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.